The finding that a high pIgR expression is associated with more favourable clinicopathological characteristics and loss thereof with an adverse clinical outcome is in line with the vast majority of hitherto published studies in other cancer forms, e.g. gastro-esophageal [12], [17], ovarian [16], bladder [14], colon [11], and non-small cell lung cancer [13]. This evidence concerns the gene PIGR and non-small cell lung carcinoma.